DISTRIBUTION OF CD4+ RORg-T Th17 AND CD25+ FOXP3+ Treg IN LEPROSY PATIEN WITH REVERSAL REACTION

Renni Yuniati, Riawan W, Widasmara D, Darmaputra IGN, Arifin S

Abstract


Objective To compare the distribution of CD4+ Th17 and CD25+ FOXP3 T regulatory cell (Treg) between  type I reversal reaction (RR) and type II reversal reaction i.e. erythema nodosum leprosum (ENL) patient groups.

 

Methods A total of 50 samples, consisted of 27 samples of reversal reaction (RR) and 23 samples of ENL, were collected. Observation of CD4+ RORg-T Th17 and CD25+ FOXP3 Treg were conducted with immunohistochemistry staining technique using anti FOX-P3 and anti RORg-T. Expression of CD4+ ROR-g Th17 and CD25+ FOXP3 Treg in percentage were analyzed using T-test.

 

Results There is a significant difference in mean CD4+ ROR-g Th17 and IL17 cell distribution for RR patient group (14.96% and 10.72%) compared with ENL (9.12% and 4.28%). No significant difference were found between mean CD25+ FOXP3 Treg and TGF-β cell distribution in RR patient group (6.12% and 5.44%) compared with ENL group (6.16% and 5.96%).

 

Conclusion There is a significant increment od CD+RORg-T Th17 and IL17 in RR patients group compared with ENL patients group. however, the distribution of CD25+ FOXP3+ Treg and TGF beta in RR has no significant difference compared with ENL.


Keywords


CD4+ RORg-T Th17, CD25+ FOXP3+ Treg, IL17, TGF-β, Reversal Reaction, Erythema Nodosum Leprosum

Full Text:

PDF

References


WHO Expert Committee on leprosy. Eight report. Geneva, World Health Organization, 2002. WHO Technical Report Series, No. 968.

Worobec SM. Current approaches and future directions in the treatment of leprosy. Trop Med. 2012;3:79-91.

Walker SL, Lockwood DNJ. (2006). The Clinical and immunological features of leprosy. Br Med Bull. 2006;77-78:103-21.

Pandhi D, Chhabra N. New Insights in The Pathogenesis of Type 1 and Type 2 Lepra Reaction. Indian J Dermatol Venereol Leprol. 2013;79:739-749.

Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345-50.

Saini C, Ramesh V, Nath I. CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, non Th2 T cells in human leprosy. PLoS Negl Trop Dis. 2013;7(7):e2338.

Sadhu S, Khaitan BK, Joshi B, Sengupta U, Nautiyal AK, Mitra DK. Reciprocity between regulatory T cells and Th17 cells: Relevance to polarized immunity in leprosy. PLoS Negl Trop Dis. 2016;10(1): e0004338.

Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14:307-8.

Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-64.

Nath I, Van Rood JJ, Mehra NK, Vaidya MC. Natural suppressor cells in human leprosy: the role of HLA-D-identical peripheral lymphocytes and macrophages in the in vitro modulation of lymphoproliferative responses. Clin Exp Immunol. 1980;42:203-10.

Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy reactions show increased Th17 cell activity and reduced FOXP3+ Tregs with concomitant decrease in TGF-beta and increase in IL-6. PLoS Negl Trop Dis. 2016;10(4):e0004592.

Vieira AP, Trindade MÂ, Pagliari C, Avancini J, Sakai-Valente NY, Duarte AJ et al. Development of type 2, but not type 1, leprosy reactions is associated with a severe reduction of circulating and in situ regulatory T-cells. Am J Trop Med Hyg. 2016;94:721-7.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014